文献速递慢性肾脏病

慢性肾脏病患者和小鼠中芳香烃受体被激活

Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney disease.
PubMed 文献 · Kidney Int · 2018-02-01

该研究在116例CKD 3至5D期患者和小鼠模型中探究芳香烃受体(AHR)激活。患者血清AHR激活潜能显著升高,与eGFR和硫酸吲哚酚浓度强相关,且AHR激活潜能高于中位数者心血管事件更频繁。小鼠5/6肾切除后血清AHR激活潜能及主动脉和心脏Cyp1a1 mRNA诱导增加,AhR-/-小鼠中缺失。

要点

  • CKD患者血清AHR激活潜能显著升高,与eGFR和硫酸吲哚酚浓度强相关。
  • CKD患者全血中AHR靶基因Cyp1A1和AHRR表达上调。
  • AHR激活潜能高于中位数的CKD患者心血管事件更频繁。

核心结论

  • AHR通路在CKD患者和小鼠中均被激活,可能是CKD心血管不良效应的关键机制。

研究设计与样本

  • 前瞻性研究纳入116例CKD 3至5D期患者,检测血清AHR激活潜能,并与健康对照比较。
  • 使用5/6肾切除小鼠模型及野生型与AhR-/-小鼠进行机制验证。

主要发现

  • CKD患者血清AHR激活潜能较健康对照显著升高,且与eGFR和硫酸吲哚酚浓度强相关。
  • CKD患者全血中AHR靶基因Cyp1A1和AHRR表达上调。
  • AHR激活潜能高于中位数的CKD患者心血管事件更频繁。
  • 5/6肾切除小鼠血清AHR激活潜能增加,主动脉和心脏Cyp1a1 mRNA诱导,AhR-/- CKD小鼠中缺失。
  • 连续注射硫酸吲哚酚后野生型小鼠血清AHR激活潜能及主动脉和心脏Cyp1a1 mRNA增加,AhR-/-小鼠中无此变化。

临床怎么用

  • 血清AHR激活潜能可能作为CKD心血管风险分层的新生物标志物。
  • 靶向AHR通路或硫酸吲哚酚可能减轻CKD相关心血管损害。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with chronic kidney disease (CKD) are exposed to uremic toxins and have an increased risk of cardiovascular disease. Some uremic toxins, like indoxyl sulfate, are agonists of the transcription factor aryl hydrocarbon receptor (AHR). These toxins induce a vascular procoagulant phenotype. Here we investigated AHR activation in patients with CKD and in a murine model of CKD. We performed a prospective study in 116 patients with CKD stage 3 to 5D and measured the AHR-Activating Potential of serum by bioassay. Compared to sera from healthy controls, sera from CKD patients displayed a strong AHR-Activating Potential; strongly correlated with eGFR and with the indoxyl sulfate concentration. The expression of the AHR target genes Cyp1A1 and AHRR was up-regulated in whole blood from patients with CKD. Survival analyses revealed that cardiovascular events were more frequent in CKD patients with an AHR-Activating Potential above the median. In mice with 5/6 nephrectomy, there was an increased serum AHR-Activating Potential, and an induction of Cyp1a1 mRNA in the aorta and heart, absent in AhR-/- CKD mice. After serial indoxyl sulfate injections, we observed an increase in serum AHR-AP and in expression of Cyp1a1 mRNA in aorta and heart in WT mice, but not in AhR-/- mice. Thus, the AHR pathway is activated both in patients and mice with CKD. Hence, AHR activation could be a key mechanism involved in the deleterious cardiovascular effects observed in CKD.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Dou L, Poitevin S, Sallée M, et al. Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney disease. Kidney Int. 2018. PMID: 29395338. doi:10.1016/j.kint.2017.11.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。